If your details change
Families who took part can contact the AZTEC team if their address, telephone number or other contact information changes.
For AZTEC families
Thank you to every family who took part
The AZTEC Trial was possible because 799 babies and their families, together with neonatal teams across the UK, contributed to a major national research study.
What was AZTEC?
The research question in plain language
Babies born very early can develop chronic lung disease because their lungs are still developing. AZTEC tested whether giving the antibiotic azithromycin soon after birth could reduce this risk and improve survival without moderate or severe chronic lung disease.
1Premature birthBabies born before 30 weeks.
2Random allocationAzithromycin or placebo.
3Close monitoringRoutine neonatal care continued throughout.
4Results & follow-upClinical outcomes and longer-term health were assessed.
What did the trial show?
The main result
Routine early azithromycin did not improve the primary outcome of survival without physiologically defined moderate or severe chronic lung disease. The study nevertheless provides important evidence for clinicians and researchers about treatment, safety, microbiology and antimicrobial resistance.
Follow-up
Keeping in touch after discharge
AZTEC families were invited to contribute follow-up information at one and two years. Questionnaires asked about health and wellbeing, allowing the research team to understand outcomes beyond the neonatal period.
If you have questions
The study team can help with questions about AZTEC participation, follow-up and how study information is used.
Privacy & choice
Participant information remains confidential
Study information is handled under the ethical and legal requirements that apply to clinical research. Identifying information is protected and access is restricted to authorised personnel involved in the study or its oversight.
Families retained the right to withdraw from study treatment or later follow-up without affecting their child’s clinical care. Information already collected may be retained where required for research integrity and regulatory obligations.